Testing day301 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called DAY301 for people with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and if it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancer types: ovarian, esophageal, triple-negative breast, non-small cell lung, small cell lung, head and neck, cervical, or endometrial cancer.
- Your cancer must be advanced or spread to other parts of the body and you must have tried standard treatments or not be able to get them.
- You must be able to provide a sample of your tumor tissue from a previous biopsy or a new one.
- You must have at least one tumor that can be measured on scans.
- You must be in good enough physical condition to be up and about (able to do light work or daily activities).
- You must not have had certain prior treatments targeting PTK7 or topoisomerase 1 inhibitors for the specific study phase.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DT-7012, given alone or with another immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if DT-7012 can shrink tumors or slow their growth.
This trial tests a new drug combo (T3011 plus a PD-1/PD-L1 inhibitor) for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
This trial tests a new drug (MTI-301) for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and shrinks tumors.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new drug called DB-1419 for people with advanced solid tumors that have not responded to other treatments. It is designed to target a protein called B7-H3 on cancer cells, and may help shrink tumors or slow their growth.
This Phase 1 study tests CPO301 in adults with advanced or metastatic solid tumors that have worsened or cannot be treated with standard options. It aims to find the safest dose and understand how the treatment affects tumors, especially in certain lung cancer groups.
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.